TerminatedPhase 3NCT05073458
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia
Studying Autoimmune hemolytic anemia, warm type
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Kathleen Butler, MDIncyte Corporation
- Intervention
- parsaclisinib(drug)
- Enrollment
- 13 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2022 – 2024
Study locations (30)
- Investigative Site US005, Los Angeles, California, United States
- Investigative Site US004, Whittier, California, United States
- Investigative Site US006, Miami, Florida, United States
- Investigative Site US012, Indianapolis, Indiana, United States
- Investigative Site US007, The Bronx, New York, United States
- Investigative Site US002, The Bronx, New York, United States
- Investigative Site US003, Greenville, North Carolina, United States
- Investigative Site US009, Canton, Ohio, United States
- Investigative Site US010, Easton, Pennsylvania, United States
- Investigative Site US001, Knoxville, Tennessee, United States
- Investigative Site AT002, Salzburg CET, Austria
- Investigative Site AT001, Vienna, Austria
- Investigative Site BE001, La Louvière, Belgium
- Investigative Site BE002, Liège, Belgium
- Investigative Site CA001, Edmonton, Alberta, Canada
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05073458 on ClinicalTrials.govOther trials for Autoimmune hemolytic anemia, warm type
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07039422Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From IanalumabNovartis Pharmaceuticals
- RECRUITINGEARLY PHASE1NCT07530380UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic AnemiaThe Second Hospital of Anhui Medical University
- RECRUITINGNANCT05925023Sirolimus in the Treatment of Refractory/Relapsed wAIHAPeking Union Medical College Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT05648968A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE2NCT05002777Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)Sanofi
- ACTIVE NOT RECRUITINGPHASE2NCT04657094Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic LeukemiaCity of Hope Medical Center